TJ004309

DRUG4 trials

Sponsors

Tracon Pharmaceuticals Inc., TJ Biopharma Co., Ltd., I-Mab Biopharma US Limited

Conditions

Advanced Solid TumorCancerGastrointestinal CancerHead and Neck CancerMetastatic CancerNon Small Cell Lung CancerOvarian CancerOvarian Carcinoma

Phase 1

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Tracon Pharmaceuticals Inc.Metastatic Cancer, Solid Tumor

Start: 2019-07-16End: 2022-06-30Target: 36Updated: 2022-04-01

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

CompletedNCT04322006

TJ Biopharma Co., Ltd.Advanced Solid Tumor

Start: 2020-05-09End: 2025-04-30Updated: 2026-05-13

Phase 2

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

CompletedNCT05001347

I-Mab Biopharma US LimitedGastrointestinal Cancer, Head and Neck Cancer, Non Small Cell Lung Cancer +3

Start: 2021-11-02End: 2023-02-08Updated: 2025-12-16

Unknown Phase

Expanded Access Study of TJ004309 in Patients With Advanced or Metastatic Cancer

I-Mab Biopharma US LimitedCancer

Updated: 2023-04-28

Related Papers

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.

Journal of Clinical Oncology2023-06-014 citations

Safety, efficacy, pharmacokinetics of uliledlimab alone or combined with toripalimab in advanced solid tumor: Initial results of a phase I/II study.

Journal of Clinical Oncology2022-06-016 citations

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

Journal of Clinical Oncology2021-05-2013 citations